Related Experiment Video
Updated: Nov 8, 2025
08:48
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12.1K
Tuning the Anti-Angiogenic Effect of the P15 Peptide Using Cyclic Trypsin Inhibitor Scaffolds
Lai Yue Chan1, Junqiao Du1, David J Craik1
1Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD 4072, Australia.
ACS Chemical Biology
|April 21, 2021
Summary
Researchers engineered a novel anti-cancer peptide (P15) into stable cyclic peptide scaffolds. The resulting compound, MCoP15, demonstrated enhanced anti-angiogenic activity and stability, offering a promising new avenue for cancer therapy development.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Tumor growth relies on angiogenesis, making anti-angiogenic strategies crucial for cancer therapy.
- The proapoptotic peptide CIGB-300 (P15-Tat) exhibits anti-angiogenic properties via the casein kinase II pathway.
- Cyclic peptides offer enhanced stability and favorable biopharmaceutical characteristics for drug design.
Purpose of the Study:
- To incorporate the P15 epitope into stable cyclic peptide scaffolds (MCoTI-II and SFTI-1) to enhance anti-angiogenic activity and stability.
- To evaluate the structural integrity and anti-angiogenic efficacy of the engineered cyclic peptides.
Main Methods:
- Design and synthesis of cyclic peptide analogs incorporating the P15 epitope into MCoTI-II and SFTI-1 frameworks.
- Nuclear Magnetic Resonance (NMR) spectroscopy to confirm secondary structures of engineered analogs.
- In vitro assays to assess inhibition of human umbilical vein endothelial cell migration and cytotoxicity.
Main Results:
- Engineered cyclic peptides maintained similar secondary structures to their native scaffolds.
- The analog MCoP15 showed significantly improved inhibition of endothelial cell migration compared to P15 alone.
- MCoP15 exhibited no cytotoxicity and demonstrated enhanced stability.
Conclusions:
- Engineering the P15 epitope into cyclic trypsin inhibitor scaffolds effectively enhances anti-angiogenic activity and stability.
- Cyclic peptide frameworks are versatile platforms for developing novel anti-angiogenic therapeutics.
- This approach holds promise for advancing antitumor therapies by targeting angiogenesis.
